| Gene symbol | NXNL1 | Synonyms | RDCVF, TXNL6 | Type of gene | protein-coding |
| Chromosome | 19 | Map location | 19p13.11 | dbXrefs | |
| Description | nucleoredoxin like 1 | ||||
| GTO ID | GTC3354 |
| Trial ID | NCT05748873 |
| Disease | Retinitis Pigmentosa |
| Altered gene | NXNL1 |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | Gene transfer |
| Treatment | SPVN06 |
| Phase | Phase1|Phase2 |
| Recruitment status | Recruiting |
| Title | A Phase I/II Study to Assess the Safety and Tolerability of a Single Subretinal Administration of SPVN06 Gene Therapy in Subjects With Rod-Cone Dystrophy (RCD) Due to a Mutation in the RHO, PDE6A, or PDE6B Gene |
| Year | 2023 |
| Country | France|United States |
| Company sponsor | SparingVision |
| Other ID(s) | SPVN06-CLIN-01 |
| Vector information | |||||||||
|
|||||||||
| Cohort 1 | |||||||
|
|||||||